Aggressive Simultaneous Radiochemotherapy with Cisplatin and Paclitaxel in Combination with Accelerated Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Tumors

Abstract

This very aggressive sRCT protocol yielded excellent response and survival figures but was associated with a very high rate of acute toxicity (8% therapy-related deaths). A maximal supportive treatment is therefore required.

Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio ­ therapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue

“…In 2003, Kuhnt et al [11] proposed a concurrent chemoradiation in which cisplatin (20 mg/m²/day) was administered on days 1-5 and 29-33 and paclitaxel (25 mg/m²/ day) was administered twice weekly for 12 cycles. This treatment led to the development of severe acute skin (grade 3: 22%) and mucosal toxicity (grade 3: 57%).…”

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

“…On the other hand, randomized studies have demonstrated the superiority of radiotherapy in combination with chemotherapy over radiotherapy alone. RCT with multiagent chemotherapy, or with hyperfractionated radiotherapy, may lead to even better outcomes, although toxicity may be increased [2,3,8,11,14,15,17,18,20,22,25,32].…”

Prognostic Factors and Significance of the Revised 6th Edition of the AJCC Classification in Patients with Locally Advanced Nasopharyngeal Carcinoma

“…Notably, concomitant chemoradiation is currently considered a standard treatment for patients with locally advanced nasopharyngeal cancer [5,8,19,29].…”